Will the FDA convene an Advisory Committee for brepocitinib DM by 2026-09-15?
Current Prediction
Why This Question Matters
An FDA Advisory Committee (AdCom) on brepocitinib DM is a leading indicator within the PDUFA process. If convened, approval probability mechanically drops 5-10% and AdCom vote becomes a proximate catalyst before PDUFA. Most Priority Review NDAs with strong Ph3 data are approved without AdCom (~75% bypass rate for orphan autoimmune). A YES (AdCom convened by 2026-09-15) would signal FDA has specific clinical or label questions requiring external review. Because this resolves before PDUFA and is itself a meaningful binary, it is valuable diagnostic information separate from the PDUFA market.
Prediction Distribution
Individual Predictions(9 runs)
Base rate for AdCom convening in priority-reviewed orphan autoimmune NDAs with clean Ph3 data is ~25-30%, elevated to ~30-35% with JAK class boxed warning considerations. However, no AdCom announcement as of April 22 is a meaningfully negative signal: AdComs are typically announced 60-90 days in advance via Federal Register, and the window from April 22 to September 15 PDUFA is ~5 months. If FDA intended an AdCom, announcement would likely have already occurred. The ~22% reflects residual probability of late-stage AdCom convening for label negotiation, partially discounted for the now-narrow announcement window.
The base rate of 25-30% for priority-reviewed orphan autoimmune AdCom convening applies to the full review period, but AdCom announcements typically come 2-4 months before PDUFA. With PDUFA likely Q3 2026 (target September 2026) and no April 22 announcement, we are already within the typical announcement window for a September PDUFA. ~50% of AdComs for this type of NDA would have been announced by now if they were going to happen. That halves the residual probability from 25-30% to roughly 12-15%. Adding back some tail for late-stage AdCom announcement (unusual but not unprecedented for JAK class) brings us to ~25%.
Decision tree with timing adjustment. P(AdCom at some point during review) ~25-30% baseline. P(announcement by September 15 | AdCom happens) ~85% (AdComs before PDUFA typically announced 45-90 days ahead; if AdCom is happening, announcement by Sept 15 for Q3 PDUFA is near-certain). P(AdCom announced between April 22 and September 15 | AdCom will happen) — we've already passed much of the typical announcement window, so conditional probability of 'announcement between now and Sept 15' given AdCom-happens is reduced. Net ~0.20-0.22.
Base rate 25-30% for priority-reviewed orphan autoimmune AdCom convening, with modest elevation for JAK class label considerations (~30-35%). Partial discount for no April 22 announcement (typical 60-90 day lead time). Conservative estimate: 0.25 reflects baseline AdCom probability with timing discount partially applied.
Slight negative tilt. VALOR Ph3 clean dataset (primary + 9/9 secondary endpoints) and severe unmet need in orphan DM favor FDA approval without external review. JAK class boxed warning is already established class-wide, reducing need for AdCom on this specific product. No April 22 announcement is meaningful. Net 0.22.
Slight positive tilt from JAK class environment post-2023. Rinvoq/Olumiant/Xeljanz safety environment has elevated FDA scrutiny on JAK approvals specifically; brepocitinib's Priority Review does not eliminate this. Base rate 25-30% + JAK class elevation gets toward 30-35%. April 22 absence modestly reduces to 0.28.
Base rate 25-30% with modest JAK class elevation. April 22 absence partial discount. Net 0.25.
Slight negative tilt. Clean VALOR data minimizes clinical questions; JAK boxed warning already class-wide. April 22 absence meaningful. Net 0.22.
Base rate 25-30% adjusted modestly for JAK class and April 22 absence. Net 0.25.
Resolution Criteria
Resolves YES if, by 2026-09-15 (approximately 2 weeks before estimated PDUFA), the FDA announces via FDA.gov, Federal Register, Roivant/Priovant 8-K, or FDA press release that an Advisory Committee meeting will be convened to review the brepocitinib DM NDA. Resolves NO if no AdCom announcement has been made by 2026-09-15, OR if the FDA approves brepocitinib DM before 2026-09-15 without convening AdCom.
Resolution Source
FDA.gov, Federal Register, Roivant/Priovant 8-K filings, FDA press releases
Source Trigger
Brepocitinib DM FDA advisory committee convened
Full multi-lens equity analysis